The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective

Table 3 Overall Survival and Value of Nivolumab

Nivo in 2nd-line	OS gains /Grade (OS/g) & HR	C/LYG	Relative Values (RV) (100,000/LYG)
Nivolumab (Nivo) vs. Doc, squamous-NSCLC [4]	96/C HR 0.59 P = 0.00025	$488,524	0.20
Nivo vs. Doc, non-squamous- NSCLC, CheckMate 057 [5]	84/C HR 0.73 P = 0.0016	$558,326	0.18
Subset analysis in > 10% positive PD-L1 ChecMate 057 [5]	264/A + HR 0.27	$177,645	0.56

Nivolumab was tabulated separately since it was the only ICPI which showed OS difference between squamous- and non-squamous histology. Nivo, Atezo and Pembro demonstrated AEs gr ¾ of < 20%, maintained/or improved the QoL and carried no black box warnings. The adverse events treatment costs (AEsTC) represented a small and insignificant fraction of drug costs and were not included in drug costs. The C/LYG were weighed relative to $100,000. Relative values (RV) were computed as $100,000/C/LYG